Experience

Davis Polk advised the joint book-running managers in connection with a $60 million SEC-registered common stock and pre-funded warrants offering by Aeglea BioTherapeutics, Inc. The common…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $115 million SEC-registered common stock offering by Revance…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 10,222,222 shares of common stock of…

Davis Polk advised the sole book-running manager of a $387.5 million SEC-registered offering of 5,000,000 shares of common stock of Alnylam Pharmaceuticals, Inc. Alnylam’s common stock is…

Davis Polk advised the sole initial purchaser in connection with a Rule 144A offering by The Medicines Company of $150 million aggregate principal amount of 3.50% convertible senior…

Davis Polk advised the sole book-runner in connection with the SEC-registered secondary offering of 10,835,145 shares of common stock of NeoGenomics, Inc. by the selling stockholder, GE…

Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the equity offering by Notre Dame Intermédica and by Bain Capital, the controlling shareholder of Notre Dame…

Davis Polk advised the representatives of several initial purchasers in connection with a Rule 144A offering by DexCom, Inc. of $850 million aggregate principal amount of its 0.75% senior…

Davis Polk advised the book-running manager and representative of the underwriters in connection with the initial public offering by Taiwan Liposome Company, Ltd. of American Depositary…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $225 million initial public offering by Orchard Therapeutics…